SCHEMBL6325652

SCHEMBL6325652

COc1cccc(OC)c1-c1noc(CCC(=O)O)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.64
ATM Q13315 1/20 0.64
MCL1 Q07820 1/20 0.55
MITF O75030 1/20 0.55
TP53 P04637 1/20 0.55
NCOA3 Q9Y6Q9 1/20 0.55
TSHR P16473 1/20 0.54
ALDH1A1 P00352 5/20 0.52
HPGD P15428 3/20 0.52
GAA P10253 2/20 0.52
ALOX15 P16050 1/20 0.52
HSD17B10 Q99714 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CYP3A4 P08684 1/20 0.51
MAPT P10636 4/20 0.51
KMT2A Q03164 1/20 0.50
FFAR1 O14842 1/20 0.50
GLA P06280 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
RXRA P19793 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6328368 0.87 ALDH1A1 (0.67) LMNAATMMCL1TP53TSHR
SCHEMBL6331512 0.86 LMNA (0.58) LMNAATMMCL1MITFTP53
SCHEMBL6324077 0.80 MCL1 (0.60) LMNAATMMCL1MITFTP53
SCHEMBL6324681 0.80 FFAR1 (0.75) LMNAATMMITFTP53NCOA3
SCHEMBL6325644 0.79 LMNA (0.68) LMNAATMMITFTP53NCOA3
SCHEMBL6325724 0.79 LMNA (0.68) LMNAATMMITFTP53NCOA3
SCHEMBL3046287 0.79 L3MBTL1 (0.62) LMNAATMTP53TSHRALDH1A1
SCHEMBL1567346 0.78 LMNA (1.00) LMNAATMMITFTP53NCOA3
SCHEMBL5330405 0.77 ALDH1A1 (0.83) LMNAATMMCL1MITFTP53
SCHEMBL6327249 0.76 LMNA (0.76) LMNAATMMITFTP53NCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 LMNA 448/4885ATM 414/4885MCL1 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.